Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin for the Prevention of Episodic Migraine
NCT07018700Phase 3Active, not recruiting
- Sponsor
- Merz
- Start
- Aug 2025
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
A Phase 3 trial of incobotulinumtoxinA in episodic migraine, sponsored by Merz. Started Aug 2025; status: active, not recruiting.
02
Drugs
incobotulinumtoxinA
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NCT07018700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07018700.